BRIEF-Jasper Therapeutics Reports Positive Data From Beacon Study Of Briquilimab In Chronic Spontaneous Urticaria

Reuters
08 Jan
BRIEF-<a href="https://laohu8.com/S/JSPR">Jasper Therapeutics</a> Reports Positive Data From Beacon Study Of Briquilimab In Chronic Spontaneous Urticaria

Jan 8 (Reuters) - Jasper Therapeutics Inc JSPR.O:

  • JASPER THERAPEUTICS REPORTS POSITIVE DATA FROM BEACON STUDY OF BRIQUILIMAB IN CHRONIC SPONTANEOUS URTICARIA

  • JASPER THERAPEUTICS INC - 66% MAINTAINED WELL CONTROLLED DISEASE AT 12 WEEKS IN 240MG COHORT

  • JASPER THERAPEUTICS INC - DATA SUPPORTS COMMENCEMENT OF CSU REGISTRATIONAL PROGRAM EXPECTED TO COMMENCE SECOND HALF OF 2025

  • JASPER THERAPEUTICS INC - 100% COMPLETE RESPONSES IN 240MG COHORT AT 8 WEEKS

Source text: ID:nGNX3fqxwC

Further company coverage: JSPR.O

((Reuters.Brief@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10